×
About 2,785 results

ALLMedicine™ Merkel Cell Carcinoma Center

Research & Reviews  944 results

Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas ...
https://doi.org/10.1007/s12022-022-09716-2 10.1146/annurev-pathmechdis-012419-032817 10.1016/j.det.2019.06.002 10.1245/s10434-021-09987-9 10.1001/jamadermatol.2020.4102 10.1016/j.jaad.2017.10.028 10.1001/jamadermatol.2014.124 10.1016/j.jid.2021.04.007 10.1111/1346-8138.15875 10.1158/1078-0432.CCR-18-4159 10.1016/j.tvr.2021.200232 10.1111/cup.13910 10.1016/j.jid.2016.10.028 10.1158/1078-0432.CCR-20-0864 10.1111/apm.12122 10.3390/cancers6031328 10.1309/AJCPIKDZM39CRPNC 10.1245/s10434-012-2509-x 10.1016/j.jaad.2020.02.034 10.1111/cup.12160 10.1186/s12885-017-3233-5 10.1097/00000372-200412000-00003 10.1111/j.1600-0560.2006.00613.x 10.1007/s12022-021-09669-y 10.1371/journal.pone.0252099 10.1016/j.humpath.2012.11.021 10.1007/s00403-020-02141-7 10.1016/S0190-9622(97)80122-3 10.1038/s41379-019-0394-6 10.1097/DAD.0000000000001548 10.1097/PAS.0000000000001136 10.1002/cncr.23874 10.1038/s41571-018-0103-2 10.1016/j.jaad.2012.09.036 10.1158/1078-0432.CCR-11-3020 10.1158/1078-0432.CCR-16-0392 10.1634/theoncologist.2020-0070 10.1007/s12022-019-09601-5 10.1016/j.hoc.2018.08.002 10.1016/j.jid.2020.02.031 10.1158/2326-6066.CIR-16-0210 10.1002/ijc.24676 10.1038/jid.2011.115 10.1016/j.ijom.2010.06.024 10.1111/j.1600-0560.2012.01964.x 10.1093/jnci/djp139 10.1038/s41379-019-0288-7 10.1016/j.jaad.2020.05.125 10.1016/j.humpath.2012.04.002 10.3390/cancers12040888 10.1371/journal.pone.0232517 10.1007/s12022-020-09640-3 10.1016/j.humpath.2014.12.001 10.1158/1078-0432.CCR-11-2308 10.1016/j.humpath.2010.09.011 10.1016/j.ajpath.2021.06.009 10.1186/s13058-015-0610-3 10.1158/0008-5472.CAN-08-4419 10.3892/ol.2015.3859 10.1038/modpathol.2013.250 10.1016/j.jaad.2012.07.035 10.1158/1078-0432.CCR-17-1678 10.1093/AJCP/AQAA051 10.1016/j.jdcr.2020.11.017
Endocrine Pathology; Santoro F, Maletta F et. al.

May 14th, 2022 - Merkel cell carcinoma is a rare and aggressive primary neuroendocrine carcinoma of the skin, whose pathogenesis can be traced back to UV radiation damage or Merkel cell polyomavirus (MCPyV) infection. Despite some improvements on the characterizat...

Merkel cell polyomavirus large T antigen binding to pRb promotes skin hyperplasia and t...
https://doi.org/10.1371/journal.ppat.1010551
PLoS Pathogens; Spurgeon ME, Cheng J et. al.

May 14th, 2022 - Clear evidence supports a causal link between Merkel cell polyomavirus (MCPyV) and the highly aggressive human skin cancer called Merkel cell carcinoma (MCC). Integration of viral DNA into the human genome facilitates continued expression of the M...

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Study
https://clinicaltrials.gov/ct2/show/NCT03712605

May 11th, 2022 - PRIMARY OBJECTIVE: I. To compare recurrence free survival (RFS) and overall survival (OS) as co-primary endpoints across the two arms. SECONDARY OBJECTIVES: I. To evaluate adverse events. II. To evaluate distant metastasis free survival (DMFS). II...

To the Editor: Patient and County-Level Factors Associated with Late Stage Merkel Cell ...
https://doi.org/10.1016/j.jid.2022.03.034
The Journal of Investigative Dermatology; Shah P, Polsky D et. al.

May 11th, 2022 - To the Editor: Patient and County-Level Factors Associated with Late Stage Merkel Cell Carcinoma at Diagnosis.|2022|Shah P,Polsky D,Shao Y,Stein J,Liebman TN,|

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
https://clinicaltrials.gov/ct2/show/NCT02155647

May 10th, 2022 - This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).

see more →

Guidelines  3 results

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0055
Journal of the National Comprehensive Cancer Network : JN... Bichakjian CK, Olencki T et. al.

Jun 13th, 2018 - This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radi...

Merkel cell carcinoma, version 1.2014.
https://doi.org/10.6004/jnccn.2014.0041
Journal of the National Comprehensive Cancer Network : JN... Bichakjian CK, Olencki T et. al.

Mar 13th, 2014 - Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative nonmelanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The NCCN Guidelines for Merkel Cell Carc...

Guidelines for the diagnosis and treatment of Merkel cell carcinoma - Cutaneous Oncolog...
https://doi.org/10.1684/ejd.2012.1694
European Journal of Dermatology : EJD; Boccara O, Girard C et. al.

Apr 14th, 2012 - Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. The epidemiological factors strongly associated with this tumor are: age over 65 years, fair skin, chronic sun exposure and immune suppression. Data are sparse in the literatu...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  30 results

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Study
https://clinicaltrials.gov/ct2/show/NCT03712605

May 11th, 2022 - PRIMARY OBJECTIVE: I. To compare recurrence free survival (RFS) and overall survival (OS) as co-primary endpoints across the two arms. SECONDARY OBJECTIVES: I. To evaluate adverse events. II. To evaluate distant metastasis free survival (DMFS). II...

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
https://clinicaltrials.gov/ct2/show/NCT02155647

May 10th, 2022 - This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
https://clinicaltrials.gov/ct2/show/NCT03599713

May 9th, 2022 - The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT03798639

Apr 26th, 2022 - PRIMARY OBJECTIVES: I. To assess the tolerability of two different experimental immunotherapy regimens in the adjuvant setting in patients with Merkel cell carcinoma (MCC). SECONDARY OBJECTIVES: I. To assess the safety and tolerability profile of ...

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04047251

Apr 19th, 2022 - Dose-escalation Phase: Approximately 48 patients are planned for the dose-escalation phase, with at least 6 patients treated at the RP2D. Cohort Expansion Phase: Four additional cohorts of 12 patients each are planned. Cohort E1: advanced ovarian ...

see more →

News  129 results

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Study Tests Novel Doublet Designed to Promote Immunity in cSCC
https://www.onclive.com/view/study-tests-novel-doublet-designed-to-promote-immunity-in-cscc

Jan 3rd, 2022 - Dan P. Zandberg, MD Investigators are testing the hypothesis that administering cetuximab (Erbitux) with an anti—PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma (cSCC). Th...

Elevated mortality seen in Merkel cell patients from rural areas
https://www.mdedge.com/dermatology/article/250046/nonmelanoma-skin-cancer/elevated-mortality-seen-merkel-cell-patients
Doug Brunk

Dec 17th, 2021 - There is an increased incidence of locally staged Merkel cell carcinoma (MCC) among patients who live in rural areas of the United States, compared with those in urban and metropolitan areas, yet overall survival is worse in rural areas. This para.

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas
https://www.onclive.com/view/pembrolizumab-chemo-not-effective-in-extrapulmonary-poorly-differentiated-neuroendocrine-carcinomas

Nov 15th, 2021 - The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs)...

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma
https://www.onclive.com/view/dr-d-angelo-on-the-incidence-and-prognosis-of-merkel-cell-carcinoma

Oct 6th, 2021 - Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the incidence and prognosis of patients with Merkel cell carcinoma (MCC). MCC is a rare cancer that affects approximately 1,000 to 2,000 individuals...

see more →

Patient Education  5 results see all →